IP Verse

Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of Schizophrenia - EP2925324

The patent EP2925324 was granted to Richter Gedeon Nyrt on Dec 30, 2020. The application was originally filed on Nov 28, 2013 under application number EP13805597A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2925324

RICHTER GEDEON NYRT
Application Number
EP13805597A
Filing Date
Nov 28, 2013
Status
Opposition Rejected
May 16, 2025
Publication Date
Dec 30, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRKASep 30, 2021HOEFER & PARTNER PATENTANWALTE MBBADMISSIBLE
WITTKOPPSep 29, 2021HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005012266
DESCRIPTIONWO2008142462
INTERNATIONAL-SEARCH-REPORTWO2008142462
INTERNATIONAL-SEARCH-REPORTWO2010126527
OPPOSITIONWO2008139235
OPPOSITIONWO2008142462
OPPOSITIONWO2010126527

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- CARPENTER W T JR ET AL, "Treatment of negative symptoms.", SCHIZOPHRENIA BULLETIN 1985, (1985), vol. 11, no. 3, ISSN 0586-7614, pages 440 - 452
EXAMINATION- KELLEY M E ET AL, "Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.", THE AMERICAN JOURNAL OF PSYCHIATRY MAR 1999, (199903), vol. 156, no. 3, ISSN 0002-953X, pages 406 - 411
EXAMINATION- NÉMETH GYÖRGY ET AL, "Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial", THE LANCET, THE LANCET PUBLISHING GROUP, GB, (20170207), vol. 389, no. 10074, doi:10.1016/S0140-6736(17)30060-0, ISSN 0140-6736, pages 1103 - 1113, XP029946666
OPPOSITION- "Guideline on clinical investigation of medical products including depot preparations in the treatment of schizophrenia", European medicines agency, (20120000), XP055849627
OPPOSITION- MÖLLER, "Clinical evaluation of negative symptoms in schizophrenia", European Psychiatry, (20070000), vol. 22, pages 380 - 386, XP022250760
OPPOSITION- MOHR et al., "The heterogeneity of schizophrenia in disease states", Schizophrenia Research, (20040000), vol. 71, pages 83 - 95, XP004564910
OPPOSITION- NEMETH et al., "Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial", The Lancet, (20170000), vol. 389, pages 1103 - 1113, XP029946666

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents